From Nasdaq:

Emergent BioSolutions signed a $235.8 million contract with the U.S. Department of Defense to supply the anthrax vaccine BioThrax for military use. The contract has a five-year base agreement with an option to extend for another five years. Emergent derives a large portion of its revenue from the sale of anthrax and smallpox vaccines to the U.S. government. They just commercially rolled out an over-the-counter version of the Narcan nasal spray for opioid overdose. Read More.

The BioThrax vaccine is the only FDA-approved vaccine for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. Anthrax is caused by Bacillus anthracis and often affects domestic and wild animals. Beyond BioThrax, Emergent also markets Cyfendus, a two-dose anthrax vaccine for post-exposure prophylaxis use in adults aged 18 and older. The company also supplies these vaccines to international non-government organizations and governments. Read More.

The indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with the DoD requires a minimum guaranteed purchase order of $20.1 million worth of the vaccine. In addition to its anthrax vaccines, Emergent also receives revenue from the sales of vaccines to the U.S. government and international organizations. The company recently achieved FDA approval for an over-the-counter version of the Narcan nasal spray for opioid overdose, which is expected to reduce its dependence on one revenue source. Read More.

CytomX Therapeutics, Novo Nordisk, and Sarepta Therapeutics are better-ranked stocks in the overall healthcare sector. CytomX Therapeutics, which carries a Zacks Rank #1 (Strong Buy), saw its earnings beat estimates in three of the last four quarters. Novo Nordisk and Sarepta carry a Zacks Rank #2. In the past 60 days, estimates for Novo Nordisk’s 2023 earnings per share have increased. Novo Nordisk’s earnings have beaten estimates in two of the last four quarters. Sarepta’s earnings per share estimates for 2024 have risen from 46 cents to $1.99. Sarepta has beaten earnings estimates in each of the last four quarters. <%= getContent.link() %>.



Read more: Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine